Company: BIAF
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001641172-25-001840
Chunk: 1394

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 8
Chunk 1394
---
ings.” In addition, designees of the placement agent for the Offering
were granted warrants to purchase an aggregate of up to 61,448 shares of Common Stock, with an exercise price of $1.50.

As
of December 31, 2024, and prior to the Offering, there were tradeable warrants to purchase up to an aggregate of 1,601,255 shares of
Common Stock outstanding and non-tradeable warrants to purchase an aggregate of up to 2,704,458 shares of Common Stock outstanding.

SCHEDULE OF CLASS OF WARRANT

    Number
    of  warrants issued  
    Weighted-average
     exercise price  
    Number
    of  warrants exercised  
    Number
    of  warrants outstanding 
  
    Pre-IPO convertible notes 
     2,900,904  
    $      5.31  
     —  
     2,900,904 
  
    IPO tradeable 
     2,326,835  
     3.06  
     (725,580) 
     1,601,255 
  
    IPO non-tradeable 
     3,015,464  
     3.06  
     (311,006) 
     2,704,458 
  
    Direct offering March 8, 2024 
     1,600,000  
     1.64  
     (1,066,667) 
     533,333 
  
    Placement agent direct offering March 8,
    2024 
     32,000  
     1.64  
     —  
     32,000 
  
    Inducement/direct offering August 5, 2024 
     1,752,082  
     1.50  
     —  
     1,752,082 
  
    Placement agent direct offering August 5,
    2024 
     49,862  
     1.50  
     —  
     49,862 
  
    Direct offering October 21, 2024 
     2,662,782  
     1.50  
     —  
     2,662,782 
  
    Placement agent direct
    offering October 21, 2024 
     61,448  
     1.50